Sangamo Therapeutics Inc. may be months away from demonstrating that its gene therapy for hemophilia A – SB-525, partnered with Pfizer Inc. – offers best-in-class sustainability of its therapeutic effect, which is crucial because competitor BioMarin Pharmaceutical Inc. is positioned to get to market first with a gene therapy for the disease.
The potential of showing “reliability” represents Sangamo’s best chance to overcome BioMarin’s expected first-to-market advantage, CEO Sandy Macrae said at...








